Download PDF
Semin Liver Dis 2007; 27: 018-025
DOI: 10.1055/s-2007-984575
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Emerging Therapies for the Management of Hepatic Encephalopathy

Nathan M. Bass1
  • 1Department of Medicine, Division of Gastroenterology; Medical Director, Liver Transplant Program, University of California, San Francisco, San Francisco, California
Further Information

Publication History

Publication Date:
14 August 2007 (online)

    Permissions and Reprints

ABSTRACT

Effective treatment options for hepatic encephalopathy (HE) are limited. Conventional therapeutic approaches are directed at reducing bacterial production of ammonia and enhancing its elimination. Nonabsorbable disaccharides are first-line therapy for HE, but published clinical studies evaluating their safety and efficacy are limited, and patient tolerance of these agents is poor. Recent data from several clinical studies support the use of rifaximin, an oral, minimally absorbed antibiotic. Rifaximin appears to be well tolerated and to confer therapeutic benefits at least comparable with, and possibly exceeding, those of nonabsorbable disaccharides and systemic antibiotics. Other potentially useful pharmacotherapies under study include acarbose, levocarnitine, and probiotics. In hospitalized patients with severe HE, the use of liver support devices (e.g., molecular adsorbent recirculating system) in the treatment of HE has shown promise in early-stage clinical investigation.

KEYWORDS

Hepatic encephalopathy - rifaximin - lactulose - levocarnitine

REFERENCES

  • 1 Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei A T. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.  Hepatology. 2002;  35 716-721
    CrossrefPubMedGoogle Scholar
  • 2 Abou-Assi S, Vlahcevic Z R. Hepatic encephalopathy: metabolic consequence of cirrhosis often is reversible.  Postgrad Med. 2001;  109 52-60, 63
    PubMedGoogle Scholar
  • 3 Riordan S M, Williams R. Treatment of hepatic encephalopathy.  N Engl J Med. 1997;  337 473-479
    CrossrefPubMedGoogle Scholar
  • 4 Blei A T, Cordoba J. Hepatic encephalopathy.  Am J Gastroenterol. 2001;  96 1968-1976
    CrossrefPubMedGoogle Scholar
  • 5 Jiang Z D, Ke S, Palazzini E, Riopel L, Dupont H. In vitro activity and fecal concentration of rifaximin after oral administration.  Antimicrob Agents Chemother. 2000;  44 2205-2206
    CrossrefPubMedGoogle Scholar
  • 6 Huang D B, DuPont H L. Rifaximin: a novel antimicrobial for enteric infections.  J Infect. 2005;  50 97-106
    CrossrefPubMedGoogle Scholar
  • 7 Pakyz A L. Rifaximin: a new treatment for travelers' diarrhea.  Ann Pharmacother. 2005;  39 284-289
    PubMedGoogle Scholar
  • 8 Paik Y H, Lee K S, Han K H et al.. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.  Yonsei Med J. 2005;  46 399-407
    CrossrefPubMedGoogle Scholar
  • 9 Mas A, Rodes J, Sunyer L et al.. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.  J Hepatol. 2003;  38 51-58
    PubMedGoogle Scholar
  • 10 Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C. Cyclic treatment of chronic hepatic encephalopathy with rifaximin: results of a double-blind clinical study.  Minerva Gastroenterol Dietol. 2003;  49 53-62
    PubMedGoogle Scholar
  • 11 Miglio F, Valpiani D, Rossellini S R, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy: a double-blind, randomised trial.  Curr Med Res Opin. 1997;  13 593-601
    CrossrefPubMedGoogle Scholar
  • 12 Williams R, James O F, Warnes T W, Morgan M Y. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study.  Eur J Gastroenterol Hepatol. 2000;  12 203-208
    CrossrefPubMedGoogle Scholar
  • 13 Bucci L, Palmieri G C. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.  Curr Med Res Opin. 1993;  13 109-118
    PubMedGoogle Scholar
  • 14 Bass N M. Review article: the current pharmacological therapies for hepatic encephalopathy.  Aliment Pharmacol Ther. 2007;  25(suppl 1) 23-31
    PubMedGoogle Scholar
  • 15 Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics: a double-blind, randomized trial.  Ital J Gastroenterol. 1991;  23 175-178
    PubMedGoogle Scholar
  • 16 Di Piazza S, Gabriella F M, Valenza L M et al.. Rifaximin versus neomycin in the treatment of portosystemic encephalopathy.  Ital J Gastroenterol. 1991;  23 403-407
    PubMedGoogle Scholar
  • 17 Puxeddu A, Quartini M, Massimetti A, Ferrieri A. Rifaximin in the treatment of chronic hepatic encephalopathy.  Curr Med Res Opin. 1995;  13 274-281
    PubMedGoogle Scholar
  • 18 Testa R, Eftimiadi C, Sukkar G S et al.. A non-absorbable rifamycin for treatment of hepatic encephalopathy.  Drugs Exp Clin Res. 1985;  11 387-392
    PubMedGoogle Scholar
  • 19 Bass N M, Ahmed A, Johnson L et al.. Rifaximin treatment is beneficial for mild hepatic encephalopathy.  Hepatology. 2004;  40(suppl 4) 646A Abstract 1116
    CrossrefPubMedGoogle Scholar
  • 20 Festi D, Mazzella G, Orsini M et al.. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety.  Curr Ther Res. 1993;  54 598-609
    CrossrefPubMedGoogle Scholar
  • 21 Parini P, Cipolla A, Ronchi M et al.. Effect of rifaximin and paromomycin in the treatment of portal-systemic encephalopathy.  Curr Ther Res. 1992;  52 34-39
    CrossrefPubMedGoogle Scholar
  • 22 Sama C, Morselli-Labate A M, Pianta P et al.. Clinical effects of rifaximin in patients with hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: an open-label, pilot study.  Curr Ther Res. 2004;  65 413-422
    CrossrefPubMedGoogle Scholar
  • 23 Lata J, Hulek P, Spicak J et al.. Safety and efficacy of rifaximin in the treatment of hepatic encephalopathy in liver cirrhosis.  Hepatology. 2002;  36(suppl 2) 519A Abstract 1425
    PubMedGoogle Scholar
  • 24 Massa P, Vallerino E, Dodero M. Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose.  Eur J Clin Res. 4 1993;  7-18
    PubMedGoogle Scholar
  • 25 Giacomo F, Francesco A, Michele N et al.. Rifaximin in the treatment of hepatic encephalopathy.  Eur J Clin Res. 1993;  4 57-66
    PubMedGoogle Scholar
  • 26 De Marco F, Amato P S, D'Arienzo A. Rifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary report.  Curr Ther Res. 1984;  36 668-674
    PubMedGoogle Scholar
  • 27 Venturini I, Ferrieri A, Farina F et al.. Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study.  Drugs Exp Clin Res. 2005;  31 161-168
    PubMedGoogle Scholar
  • 28 Als-Nielsen B, Gluud L L, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials.  BMJ. 2004;  328 1046
    CrossrefPubMedGoogle Scholar
  • 29 Sigal S H, Stanca C M, Kontorinis N, Bodian C, Ryan E. Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis.  Am J Gastroenterol. 2006;  101 1490-1496
    CrossrefPubMedGoogle Scholar
  • 30 Gentile S, Guarino G, Romano M et al.. A randomized controlled trial of acarbose in hepatic encephalopathy.  Clin Gastroenterol Hepatol. 2005;  3 184-191
    CrossrefPubMedGoogle Scholar
  • 31 Levocarnitine Injection USP [prescribing information]. Available at: http://www.bedfordlabs.com/products/inserts/levocarnitine_pi.pdf Accessed March 29, 2007
    Google Scholar
  • 32 Raskind J Y, El Chaar G M. The role of carnitine supplementation during valproic acid therapy.  Ann Pharmacother. 2000;  34 630-638
    CrossrefPubMedGoogle Scholar
  • 33 Siciliano M, Annicchiarico B E, Lucchese F, Bombardieri G. Effects of a single, short intravenous dose of acetyl-L-carnitine on pattern-reversal visual-evoked potentials in cirrhotic patients with hepatic encephalopathy.  Clin Exp Pharmacol Physiol. 2006;  33 76-80
    CrossrefPubMedGoogle Scholar
  • 34 Malaguarnera M, Pistone G, Elvira R, Leotta C, Scarpello L, Liborio R. Effects of L-carnitine in patients with hepatic encephalopathy.  World J Gastroenterol. 2005;  11 7197-7202
    PubMedGoogle Scholar
  • 35 Malaguarnera M, Pistone G, Astuto M et al.. Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial.  Dig Dis Sci. 2006;  51 2242-2247
    CrossrefPubMedGoogle Scholar
  • 36 del Olmo J A, Castillo M, Rodrigo J M et al.. Effect of L-carnitine upon ammonia tolerance test in cirrhotic patients.  Adv Exp Med Biol. 1990;  272 197-208
    PubMedGoogle Scholar
  • 37 Sushma S, Dasarathy S, Tandon R K, Jain S, Gupta S, Bhist M S. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial.  Hepatology. 1992;  16 138-144
    PubMedGoogle Scholar
  • 38 Efrati C, Masini A, Merli M, Valeriano V, Riggio O. Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution.  Am J Gastroenterol. 2000;  95 3574-3578
    CrossrefPubMedGoogle Scholar
  • 39 Mendenhall C L, Rouster S, Marshall L, Weesner R. A new therapy for portal systemic encephalopathy.  Am J Gastroenterol. 1986;  81 540-543
    PubMedGoogle Scholar
  • 40 Liu Q, Duan Z P, Ha D K, Bengmark S, Kurtovic J, Riordan S M. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis.  Hepatology. 2004;  39 1441-1449
    CrossrefPubMedGoogle Scholar
  • 41 Lighthouse J, Naito Y, Helmy A et al.. Endotoxinemia and benzodiazepine-like substances in compensated cirrhotic patients: a randomized study comparing the effect of rifaximine alone and in association with a symbiotic preparation.  Hepatol Res. 2004;  28 155-160
    PubMedGoogle Scholar
  • 42 Sen S, Mookerjee R P, Davies N A, Williams R, Jalan R. Review article: the molecular adsorbents recirculating system (MARS) in liver failure.  Aliment Pharmacol Ther. 2002;  16(suppl 5) 32-38
    CrossrefPubMedGoogle Scholar
  • 43 Heemann U, Treichel U, Loock J et al.. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study.  Hepatology. 2002;  36 949-958
    CrossrefPubMedGoogle Scholar
  • 44 Hassanein T, Tpfteng F, Brown Jr R et al.. Efficacy of albumin dialysis (MARS) in patients with cirrhosis and advanced grades of hepatic encephalopathy: a prospective, controlled, randomized multicenter trial [abstract].  Hepatology. 2004;  4(suppl 1) 726A
    PubMedGoogle Scholar

Nathan M BassM.D. Ph.D. 

Professor of Medicine, Department of Medicine, Division of Gastroenterology, University of California, San Francisco

357-S. Box 0538, 513 Parnassus Avenue, San Francisco, CA 94143-0538

      >